Heterocyclic AAK1 Inhibitors With Scaffold Tuning for Potency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing AAK1 inhibitor compounds do not effectively inhibit the activity of adaptor associated kinase 1 (AAK1), which is implicated in various diseases such as schizophrenia, Parkinson's disease, and Alzheimer's disease.
Innovation Solution
Development of nitrogen-containing heterocyclic compounds and their stereoisomers or pharmaceutically acceptable salts, which exhibit strong AAK1 inhibitory activity, including specific structures defined by variables X1, X2, X3, R1, R2, R3, R4, R5, and R6, and n, as well as various ring configurations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing AAK1 inhibitor compounds are used, then the structure is known and available, but the inhibitory activity against AAK1 is insufficient
Solution Approach 1:
The patent divides the AAK1 inhibitor molecule into distinct functional segments: a heterocyclic core structure (X1, X2, X3 being N or CR2), substitutable position groups (R1-R6), and variable ring configurations. This segmentation allows independent optimization of each segment's contribution to binding affinity and selectivity, thereby improving AAK1 inhibitory activity while maintaining structural diversity through combinatorial variation of the segmented elements.
Solution Approach 2:
The patent applies local quality by allowing specific positions in the molecule (R1-R6) to have different substituent options tailored to optimize local interactions with the AAK1 binding pocket. Each position can be independently substituted with groups having different electronic, steric, and hydrophobic properties, enabling fine-tuning of local binding characteristics to enhance overall inhibitory activity.
2Reliability
If novel nitrogen-containing heterocyclic compounds are developed to improve AAK1 inhibitory activity, then the inhibitory effect increases, but the complexity of compound structure increases
Solution Approach 1:
The patent creates a universal heterocyclic scaffold (X1, X2, X3 being N or CR2) that serves as a multi-functional core capable of supporting diverse substituent patterns (R1-R6) and ring configurations. This universal core structure maintains consistent binding to AAK1 while allowing combinatorial variation of substituents to achieve high inhibitory activity without proportionally increasing molecular complexity. The standardized core reduces the complexity burden compared to entirely novel structures.
Solution Approach 2:
The patent systematically varies key structural parameters including: the identity of X1, X2, X3 (N or CR2), the nature of substituents at R1-R6 positions, the type of ring A, and the value of n (0-4). By changing these parameters in a controlled manner, the patent optimizes AAK1 inhibitory activity while maintaining manageable structural complexity through defined variation ranges rather than unlimited structural freedom.
Data Source
Figure 1
AI summary
The present invention relates to use of a nitrogen-containing heterocyclic compound or a pharmaceutically acceptable salt thereof for inhibiting activity of adaptor associated kinase 1 (AAK1 kinase) in a medicament for treating or preventing a disease or a disorder mediated by the activity of AAK1. Specifically, the present invention provides a compound of formula I, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, where a definition of each group is as described in the specification. The compound has relatively high AAK1 inhibitory activity. (FIG. 1)